| RPA Group | ||||
---|---|---|---|---|---|
 | Group 1 | Group 2 | Group 3 | Group 4 | P value |
Overall survival | Â | Â | Â | Â | Â |
3-yrs (%) | 91.5 | 84.1 | 65.7 | 45.2 | < 0.001 |
5-yrs (%) | 85.6 | 78.3 | 54.8 | 35.1 | < 0.001 |
HR | 1.00 | 1.70 | 4.12 | 7.88 | Â |
95% CI | Â | 1.44-1.99 | 3.56-4.78 | 6.71-9.25 | Â |
Progression-free survival | Â | Â | Â | Â | Â |
3-yrs (%) | 94.2 | 86.0 | 69.4 | 51.7 | < 0.001 |
5-yrs (%) | 90.4 | 81.4 | 60.6 | 41.7 | < 0.001 |
HR | 1.00 | 2.25 | 5.42 | 9.91 | Â |
95% CI | Â | 1.85-2.74 | 4.52-6.51 | 8.16-12.11 | Â |
Cancer-specific survival | Â | Â | Â | Â | Â |
3-yrs (%) | 94.5 | 87.5 | 70.5 | 52.1 | < 0.001 |
5-yrs (%) | 91.1 | 83.2 | 61.9 | 43.2 | < 0.001 |
HR | 1.00 | 2.13 | 5.52 | 10.56 | Â |
95% CI | Â | 1.74-2.60 | 4.58-6.66 | 8.66-12.90 | Â |